ascopubs.org

Inference of sample-specific genetic interactions to increase accuracy of indication prioritization in oncology clinical trials and facilitate exploration of combined therapy ...

Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.
Institute for Fiscal Studies

A primer on power and sample size calculations for randomisation inference with experimental data

This paper revisits the problem of power analysis and sample size calculations in randomised experiments.